Poseida Therapeutics aims for $115m stock market launch to fund CAR-T R&DCalifornia biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last Share XPoseida Therapeutics aims for $115m stock market launch to fund CAR-T R&Dhttps://pharmaphorum.com/news/poseida-therapeutics/
Mixed results for Roche drugs in prostate cancer and COVID-19Two eye-catching research projects involving drugs from Roche have produced disappointing trial results, after its prostate cancer drug Share XMixed results for Roche drugs in prostate cancer and COVID-19https://pharmaphorum.com/news/mixed-results-for-roche-drugs-in-prostate-cancer-and-covid-19/
AZ/Merck & Co take on Clovis as FDA approves prostate cancer drugThe FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator Share XAZ/Merck & Co take on Clovis as FDA approves prostate cancer drughttps://pharmaphorum.com/news/az-merck-cos-lynparza/
Clovis steals march on AZ with PARP prostate approvalShares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP Share XClovis steals march on AZ with PARP prostate approvalhttps://pharmaphorum.com/news/clovis-steals-march-on-az-with-parp-prostate-approval/
Xtandi takes fight to prostate cancer rivals with survival dataPfizer and Astellas have new survival data for their prostate cancer drug Xtandi that could help it fend Share XXtandi takes fight to prostate cancer rivals with survival datahttps://pharmaphorum.com/news/xtandi-takes-fight-to-prostate-cancer-rivals-with-survival-data/
AZ and MSD’s Lynparza gets fast prostate cancer FDA reviewThe FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the Share XAZ and MSD’s Lynparza gets fast prostate cancer FDA reviewhttps://pharmaphorum.com/news/az-and-msds-lynparza-gets-fast-prostate-cancer-fda-review/
Clovis takes PARP prostate cancer pole position with fast FDA review of RubracaThe FDA has granted a fast review for Clovis Oncology’s Rubraca PARP drug in certain patients with prostate Share XClovis takes PARP prostate cancer pole position with fast FDA review of Rubracahttps://pharmaphorum.com/news/clovis-takes-parp-prostate-cancer-pole-position-with-fast-fda-review-of-rubraca/
AZ sells ex-US rights to old cancer drugs Arimidex and CasodexFor several years AstraZeneca has been selling off rights to its older drugs to raise cash as it Share XAZ sells ex-US rights to old cancer drugs Arimidex and Casodexhttps://pharmaphorum.com/news/az-sells-ex-us-rights-to-old-cancer-drugs-arimidex-and-casodex/
Xtandi catches up with Erleada in castration-sensitive prostate cancerPfizer and Astellas have bagged FDA approval for Xtandi in metastatic castration-sensitive prostate cancer (CSPC), cancelling out a Share XXtandi catches up with Erleada in castration-sensitive prostate cancerhttps://pharmaphorum.com/news/xtandi-catches-up-with-erleada-in-castration-sensitive-prostate-cancer/
